

August 1, 2025

To whom it may concern:

Company Name: TAIYO HOLDINGS CO., LTD.  
Representative: Hitoshi Saito, President, and CEO  
(Code: 4626, Listed on Prime  
Market of Tokyo Stock Exchange)  
Inquiries: Sayaka Tomioka, Managing  
Executive Officer, CFO  
Tel: +81-3-5953-5200 (main line)

## Notice Regarding “2030 Committee Interim Report”

As announced in the "Notice Regarding the Establishment of a 2030 Committee" dated May 28, 2025, and the "Notice Regarding the Details of a 2030 Committee" dated June 12, 2025, Taiyo Holdings Co., Ltd. (hereinafter “Taiyo Holdings”) has established the 2030 Committee as a forum that ensures objectivity and transparency with the aim of enhancing medium- to long-term corporate value and securing the common interests of shareholders, and has been proceeding with the 2030 Committee’s activities accordingly.

Today, Taiyo Holdings hereby reports the current status (interim report) of the activities of the 2030 Committee as set forth below. For more information, please refer to the attached materials.

### 1. Progress in Each Working Group (WG) and Future Acton

#### (1) WG for strengthening the foundation

- The WG has gained an understanding of the mechanisms and environment through which we have developed the “self-sufficient personnel” valued with the company. It has also reviewed activities to date as well as future priority measures.
- With the issuance of this Interim Report, the review has been largely completed. If any new points for consideration emerge, additional review will be conducted.

#### (2) WG for growth strategy and business portfolio

- After gaining an understanding of the business environment in the Electronics business, the strategies for “manufacturing and marketing” and “contract manufacturing” in the Medical and Pharmaceuticals business, and quantitative aspects of these businesses, the WG commenced discussions on our business portfolio.
- In late August, a medium-term management plan based on results of review by this WG will be announced.

#### (3) WG for capital allocation

- Based on the review results of the WG for growth strategies and business portfolio, further considerations will be conducted, and the medium-term management plan reflecting the findings of this WG is scheduled to be announced in late August.

#### (4) WG for governance

- A review of the succession plan for key positions, including Mr. Sato, a Senior Corporate Executive Manager, was conducted under the leadership of the Nomination and Compensation Committee
- The WG intends not only to establish a governance system, but also to consider initiatives to further enhance its effectiveness.

(5) WG for shareholder and investor relations

- The status of dialogues with shareholders and investors to date was reviewed, and measures to further enhance dialogues were considered.
- The establishment of new opportunities for dialogue between Outside Directors and investors, among other topics, is currently being reviewed.
- With the issuance of this Interim Report, the review has been largely completed. If any new points for consideration emerge, additional review will be conducted.

(6) WG for capital policy

- Based on the review results of the WG for growth strategies and business portfolio, further considerations will be conducted, and the medium-term management plan reflecting the findings of this WG is scheduled to be announced in late August. Thereafter, initiatives toward the final report to be issued in November will proceed.
- The special committee is currently reviewing various proposals submitted by private equity funds and operating companies.

## 2. Future Outlook

Late August 2025:	Announce a mid-term management plan based on the 2030 Committee's activities
November 2025:	Release a final report alongside the second-quarter financial results

# 2030 Committee Interim Report


Taiyo Holdings Co., Ltd. | August 1, 2025

**2025**

# Purpose of 2030 Committee and Review Structure (Restated)

- We have established the 2030 Committee to examine and address various management challenges, including the formulation of a medium-term management plan, with the aim of realizing our long-term management plan for 2030. We have built a process that ensures objectivity and transparency and a system that leverages the knowledge of outside experts.
- Additionally, we have set up a special committee composed of outside board directors and an external expert to conduct a fair, transparent, and objective comparison and evaluation of the capital policy to be considered by the Board of Directors, and to make recommendations to the Board of Directors.

## Review structure based on the establishment of the 2030 Committee



# Matters for review by 2030 Committee (Restated)

- We have established working groups (WGs) for each agenda item under the 2030 Committee. Each WG is composed of internal and external members who are well-suited for each agenda item. These members are currently pursuing concrete reviews of agenda.

## Matters for review

### 1 WG for strengthening the foundations

- Considers approaches to developing self-sufficient personnel and digital transformation, both of which support the foundation of the company's continued growth
- Reviews the process of developing self-sufficient personnel in light of future growth strategies

### 2 WG for growth strategy and business portfolio

- Reviews the ideal business portfolio. Particularly reassess the positioning of the Medical and Pharmaceuticals business within the entire company, as a certain period of time has elapsed since its market entry
- Reviews growth strategies, including M&A, to formulate the medium-term management plan

### 3 WG for capital allocation

- Reviews the optimal capital allocation based on the recommendation of the WG for growth strategy and business portfolio
- Confirms and evaluates investment discipline in new businesses, M&A, etc.
- Develops an appropriate shareholder return policy

### 4 WG for governance

- Aims to establish a corporate governance structure that earns the trust of general shareholders
- Examines the current corporate governance issues and considers measures to improve effectiveness
- Reviews succession plans

### 5 WG for shareholder and investor relations

- Consider methods of dialogue with shareholders and investors
- Reevaluate the appropriate approach to information disclosure (both financial and non-financial) and investor relations initiative

### 6 WG for capital policy

- Review the ideal capital policy to be adopted from the perspective of enhancing corporate value and securing shareholders' common interests through the achievement of Beyond Imagination 2030

# Progress of Review by 2030 Committee

- So far, we have mainly reviewed (1) WG for strengthening the foundation, (2) WG for growth strategy and business portfolio, (4) WG for governance, (5) WG for shareholder and investor relations. Matters regarding business plans will be reported at the end of August.

## Progress of review to date

### 1 WG for strengthening the foundations

- The WG has gained an understanding of **the mechanisms and environment through which we have developed the "self-sufficient personnel"** valued with the company. It has also reviewed activities to date as well as future priority measures.

### 2 WG for growth strategy and business portfolio

- After **gaining an understanding of the business environment in the Electronics business, the strategies for "manufacturing and marketing" and "contract manufacturing" in the Medical and Pharmaceuticals business, and quantitative aspects of these businesses**, the WG commenced **discussions on our business portfolio**.

### 3 WG for capital allocation

- Scheduled to be reviewed following (2)

### 4 WG for governance

- A review of **the succession plan for key positions, including Mr. Sato**, was conducted under the leadership of the Nomination and Compensation Committee.
- **Specific details of this WG are scheduled to be released in the final report in November.**

### 5 WG for shareholder and investor relations

- The status of dialogues with shareholders and investors to date was reviewed, and **measures to further enhance dialogues were considered**.
- The establishment of new opportunities for dialogue between Outside Directors and investors, among other topics, is currently being reviewed.

### 6 WG for capital policy

- Scheduled to be reviewed following (2)

# **(1) WG for Strengthening the Foundations**


---



# Overview of Initiatives to Strengthen the Foundations

- As outlined in the basic policy under the long-term management plan, we are focusing on **the development of self-sufficient personnel** and **the promotion of digital transformation (DX)** as foundations for supporting sustainable growth.

## Key initiatives to strengthen the foundations



### Development of self-sufficient personnel

- We define self-sufficient personnel as “individuals who, based on their own will, set their own goals, proactively carry out their tasks, and enjoy both the process of achieving those goals and producing results,” and we have been engaged in cultivating such human resources.
- As a company-wide initiative, we implemented the **"Co-Creation Initiative for the Future"** in 2019. We also focused on organizational transformation, including the release of "Taiyo Values" in 2021.
- From 2025, we have promoted individual measures tailored to each organization, driven by managerial personnel. For the development of self-sufficient personnel, we have shifted our focus to **activities aimed at strengthening management capabilities**.

### Promotion of DX


- As a means of **strengthening the foundation for promoting DX**, we undertook infrastructure integration, standardization of master data, and introduction of ERP systems, among other efforts. We also worked on developing DX personnel.
- As part of **"Defensive DX,"** we have improved productivity and enhanced operations, while having promoted the creation of new businesses based on in-house accumulated data and experience as part of **"Offensive DX."**



## Development of Self-Sufficient Personnel: Enhancement of Shareholder Value through Human Resource Measures

- Taking the position that human resources, more than anything else, are the foundations of a company's sustainable growth and enhancement of our shareholder value, we carried out HR measures linked to our management strategy with the development of self-sufficient personnel at their core. These initiatives have produced results, such as lower turnover, new business growth, and improved labor productivity.
- In turn, these efforts lead to enhanced shareholder value by improving ROE and ROIC and promoting profit growth.


### Enhancement of shareholder value through human resource measures



# Initiatives to Date and Future Initiatives

- Up to this point, we have continued to focus on human capital investment with a view to enhancing shareholder value. Even as the company continues to grow, we will promote flexible measures with the aim of "developing and utilizing self-sufficient personnel," which is a basic policy under the long-term management plan.

## Example of measures aimed at developing self-sufficient personnel



## ① WG for strengthening the foundation

# Development of Self-Sufficient Personnel: Case Example A - Co-Creation Initiative for the Future

- For the "Co-Creation Initiative for the Future," we implemented two key components: the "Future Co-Creation Meetings," where individuals and teams share their visions and current situations, and the "Taiyo Values<sup>\*1</sup>," which sets forth as values which all employees should treasure.
- These two initiatives have already begun to bring about various changes among individuals and within organizations.

## Overview of the Co-Creation Initiative for the Future and its main results

### Co-Creation Initiative for the Future

#### ① Co-Creation for the Future Meetings

- Implemented with the aim of fostering strong individuals and a strong organization by acquiring a Growth Mindset<sup>\*2</sup> and enhancing the quality of team relationships and behavior.
- Held repeatedly **to share visions and current statuses at both individual and team levels.**

#### ② Application of the Taiyo Values

- Created as **values that all Group employees should treasure by our employees and management team**, and released in October 2021.
- **"Value Leaders"** are selected so that each individual employee may embody the Taiyo Values. Also, **"offsite sessions"** are conducted to share each team's vision and review materialization process.

### Main results

- At workplaces where "Future Co-Creation Meetings" were held, **ongoing dialogue significantly enhanced communication and mutual understanding among members.**
- Outside of these activities as well, there was progress in the **embedding of the values in daily work**, such as the use of keywords related to the "Taiyo Values."

\*1 The values of placing importance on "enjoy," "speed," "sincerity," and "communication."

\*2 The concept advocated by Stanford University Professor Carol Dweck, which proposes that one's own growth can be fostered through experience and effort.


## ① WG for strengthening the foundation

# Development of Self-Sufficient Personnel: Case Example B - Enhancement of Management Capabilities

- Starting in 2025, we aim to create a virtuous cycle of "member and team growth" together with "organizational and business growth," led by managers.

## Initiatives to enhance management capabilities

### Maximize team performance



Managers

Creating a cycle of human resource and organizational development tailored to each organization through leadership by managers

### Management support tools

- e-learning** : Deepening the understanding of management roles and key points
- Handbook** : Providing tips for creating opportunities for open discussion within management processes
- Career Dialogue Sheet** : Supporting self-assessment aimed at career autonomy

### Opportunities, mechanisms, and systems provided

- HR development system** : Providing opportunities for development and growth based on expected roles
- Organization of information platforms** : Supporting each individual in thriving through the use of human resource data

### Understanding the status of organizations and personnel

- Engagement surveys** : Offering a bird's-eye view of organizations and their members, contributing to the building of better teams

## **(2) WG for Growth Strategy and Business Portfolio**

---



# WG for Growth Strategy and Business Portfolio

- After deepening our understanding of the company through business hearings, site visits, and other initiatives, we have started discussions regarding the business portfolio, taking into consideration factors such as future growth potential and profitability. Particularly for the Medical and Pharmaceuticals business, we are assessing growth strategies and the positioning of the business based on our understanding and discussions of the external environment for both the manufacturing and marketing of long-listed products and the contract manufacturing business.
- A business plan will be announced at the end of August, and we will conduct further examinations for the final report scheduled in November.

## Status of Considerations

### Business hearings

- Conducted interviews and discussions with each group company to deepen our understanding of their businesses
  - Organized the growth potential of the Electronics business and analyzed the business environment, including foreign exchange trends and the silicon cycle
  - Reviewed the transitions in the Medical and Pharmaceuticals business since its market entry
    - ✓ Changes in the external environment, background of impairment losses, and potential and methods for improving profitability of the manufacturing and marketing of long-listed products
    - ✓ Potential for expansion and associated risks of the contract manufacturing business

### Topics discussed by the 2030 Committee

- Reviewed the company's business plan
- Examined the relationship between the Electronics business and the Medical and Pharmaceutical business
- Discussed policies to address management challenges in the Electronics business, such as foreign exchange risks and the silicon cycle
- Examined the relationship between the “manufacturing and marketing” and “contract manufacturing,” within the Medical and Pharmaceuticals business
  - ✓ Monitored trends among industry peers
  - ✓ Discussed the growth potential and asset efficiency of each business
  - ✓ Considered potential options for the business portfolio, as well as their feasibilities, advantages and disadvantages

## **(4) WG for governance**


---



# Initiatives to date

- We have continuously made efforts to reinforce the supervisory functions of our Board of Directors, such as transitioning to a company with an Audit and Supervisory Committee in June 2024, and adopting a Board composition with the majority of outside board directors in June 2025.

## Initiatives to strengthen governance to date






# Board of Directors Composition


- Outside board directors comprise the majority of the Board of Directors, which is chaired by an outside board director. Additionally, a Nomination and Compensation Committee has been established with all members being outside board directors.
- This Board of Directors composition ensures independence and objectivity.

## Board of Directors composition




# Succession Plan 1/2

- We aim to enhance the effectiveness of our succession plan through the following steps, ideally by the end of October.



## Succession Plan 2/2

- We will formulate and operate highly transparent succession plans through objective evaluations of personnel based on external assessments, and by involving the Nomination and Compensation Committee, which is comprised solely of outside board directors.
- Over the medium to long term, we also intend to seek external candidates as potential successors.



# Matters for Future Review

- We intend not only to establish a governance system, but also to consider initiatives to further enhance its effectiveness.
- In particular, the design of the succession plan is especially important from the perspectives of sustainable growth and the enhancement of corporate value over the medium to long term. We plan to release specific details in its final report in November.

## Main matters for review in the future

### Succession plan design

- We will **design a succession plan for management executives, including Mr. Sato, a Senior Corporate Executive Officer** as an interim measure, and will establish a system to appropriately operate a succession plan.
- We will continue working to strengthen the effectiveness of this plan, focusing mainly on key positions at Taiyo Holdings and on presidents of key subsidiaries, ideally by the end of October. We plan to release further details in the final report in November.

### Effectiveness evaluations of the Board of Directors (Third-party evaluations)

- Effectiveness evaluations of the Board of Directors are regularly conducted with the use of questionnaires administered to board directors.
- These evaluations are performed solely in-house. Going forward, we will consider engaging **a third party with expertise in governance to secure a more objective evaluation process.**

### Holding of Executive Sessions

- **Executive Sessions consisting solely of Outside Board Directors** are held on a regular basis.
- Outside board directors held discussions without the attendance of executive board directors, and provided feedback to the executive management in order to strengthen the executive function.

## **(5) WG for Shareholder and Investor Relations**

---



## Status of Implementation of Dialogue with Shareholders and Investors (fiscal year ended March 2025) 1/2

- To date, we have continuously engaged in dialogues with shareholders and investors through various briefings and one-on-one meetings.

### Records of dialogues for the fiscal year ended March 2025 (1/2)

Matters implemented	Frequency	Persons responsible at Taiyo Holdings (Titles are those at the time of handling)
Financial results briefings for investors (Full year/1 <sup>st</sup> half)	2 times	<ul style="list-style-type: none"> <li>Handled by President &amp; CEO and Managing Executive Officer &amp; CFO</li> <li>Attended by analysts, fund managers, etc.</li> </ul>
Company briefings for institutional investors	1 time	<ul style="list-style-type: none"> <li>Handled by President &amp; CEO, Senior Corporate Executive Officer &amp; CTO, and Managing Executive Officer &amp; CFO</li> <li>Attended by analysts, fund managers, etc.</li> </ul>
Company briefings for individual shareholders (On-demand streaming)	1 time	<ul style="list-style-type: none"> <li>Handled by President &amp; CEO and Managing Executive Officer &amp; CFO</li> <li>Received advance questions</li> </ul>
Visiting domestic sites for analysts / institutional investors	1 time	<ul style="list-style-type: none"> <li>Handled by President &amp; CEO, Senior Corporate Executive Officer &amp; CTO, and Corporate Planning Department personnel</li> </ul>

## Status of Implementation of Dialogue with Shareholders and Investors (fiscal year ended March 2025) 2/2

- In the fiscal year ended March 2025, we held approximately 200 one-on-one meetings with institutional investors and analysts.
- In addition to actively communicating information on our situation, we have also made efforts to gain an understanding of capital market perspectives and valuations.

### Records of dialogues for the fiscal year ended March 2025 (2/2)

Matters implemented	Frequency	Persons responsible at Taiyo Holdings (Titles are those at the time of handling)
Small group meetings with institutional investors	3 times	<ul style="list-style-type: none"> <li>• (1) Handled by President &amp; CEO, Senior Corporate Executive Officer &amp; CTO, and Managing Executive Officer &amp; CFO</li> <li>• (2) Handled by Managing Executive Officer &amp; CFO and Corporate Planning Department personnel</li> <li>• (3) Handled by Managing Executive Officer &amp; CFO and Corporate Planning Department personnel</li> </ul>
IR conferences for overseas investors	1 time	<ul style="list-style-type: none"> <li>• Handled by Managing Executive Officer &amp; CFO</li> <li>• Held meetings with overseas investors</li> </ul>
One-on-one meetings with institutional investors / analysts	Almost 200 times	<ul style="list-style-type: none"> <li>• Over 90% of meetings handled by Managing Executive Officer &amp; CFO</li> </ul>
(Domestic institutional investors)	(100 times)	
(Overseas institutional investors)	(70 times)	
(Analysts)	(30 times)	

# Main Dialogue Themes

- Dialogues with shareholders and investors mainly focused on themes related to the Electronics business.

Dialogue theme	Content
<b>Overall management strategy and long-term management plan</b>	<ul style="list-style-type: none"> <li>Methods for achieving an ROE of 18%</li> <li>Background of changes in shareholder return policy and guideline on timing for the purchase of treasury shares</li> <li>Policy for executing M&amp;As, key KPIs, and future targets</li> <li>Approach to business portfolio (background for entering into Medical and Pharmaceuticals business, associated strategy, etc.)</li> </ul>
<b>Electronics Business</b>	<ul style="list-style-type: none"> <li>Background of strong performance in smartphone- and automotive-related products and future forecasts</li> <li>Status of entry into growth markets for PKG substrates</li> <li>Trends in new products and status of their adoption</li> <li>Progress in the adoption of dry film (DF) for rigid high-end products</li> <li>Effects of tariffs by the U.S. Trump administration and trends in China</li> <li>Exchange rate sensitivity and monetary impact</li> <li>Status of construction of Production Engineering Center at Tsurugashima</li> </ul>
<b>Medical and Pharmaceuticals Business</b>	<ul style="list-style-type: none"> <li>Effects of NHI drug price revisions and the elective care scheme for long-listed products</li> <li>Background of recording of impairment losses and future outlook</li> <li>Future investment plans</li> <li>Plant operating capacity and progress of new orders</li> <li>Expected future contribution and time frame for mystarz</li> </ul>
<b>Sustainability</b>	<ul style="list-style-type: none"> <li>Activities of Sustainability Promotion Committee and human capital management initiatives</li> <li>Effects and progress of the transition to a company with Audit and Supervisory Committee</li> </ul>



## Feedback to Management and Board Directors and Incorporated Matters

- The results of dialogues with shareholders and investors are fed back to management and the Board of Directors, after which matters to be incorporated are discussed as appropriate.
- In the fiscal year ended March 2025, measures such as improvements to financial results briefings and the holding of business briefings were implemented.

### Feedback to management and board directors and incorporated matters

Method of feedback	Frequency	Content
Quarterly regular report	4 times	<ul style="list-style-type: none"> <li>• Reports on status of dialogues with shareholders and investors were presented at the Board of Directors meeting in each quarter.</li> <li>• Management identified the concerns of shareholders and investors and discussed matters to be incorporated as necessary.</li> </ul>
Sharing of meeting records	As needed	<ul style="list-style-type: none"> <li>• Dialogue content is organized in the form of minutes and shared with Board Directors as necessary</li> </ul>



Incorporated Matters	Content
Enhancement of financial results briefing materials	<ul style="list-style-type: none"> <li>• Published the financial results briefings materials, along with accompanying scripts of dialogues for investors who were unable to attend briefings</li> </ul>
Timely disclosure of financial results briefing materials	<ul style="list-style-type: none"> <li>• Made timely disclosures of financial results briefing materials to the Tokyo Stock Exchange in order to ensure fair disclosure</li> </ul>
Changes to the timing of financial results briefings	<ul style="list-style-type: none"> <li>• Changed the timing of financial results briefings to make it easier for investors to attend briefings</li> </ul>
Holding of company briefings	<ul style="list-style-type: none"> <li>• Held company briefings in addition to financial results briefings (now held on a regular basis)</li> </ul>

# Matters for Future Review

- Going forward, we will review initiatives for the following matters in order to strengthen dialogues with shareholders and investors.

## Main matters for consideration going forward

### Dialogues between outside board directors and investors

- We will arrange opportunities for outside board directors to engage in direct dialogue with investors.
- Outside Board Directors will gain an understanding of how investors view the company's situation. Perspectives deemed useful will be incorporated into discussions at Board the of Directors meetings.

### Disclosure of dialogue contents with investors

- Matters and dialogue contents that attracted numerous questions will be disclosed.
- We will provide information to general shareholders and others who have limited opportunities for direct dialogue and will work to foster greater interest from institutional investors to promote understanding.

### Holding of IR Day

- We will hold IR Days for institutional investors and analysts to engage in dialogue regarding topics such as our business and financial strategy, governance structure, and sustainability initiatives.
- In addition to fostering a deeper comprehensive understanding, we will gain an understanding of capital market perspectives and valuations on a wide range of themes, not limited to business aspects alone.

# Summary and Next Steps

---



# 2030 Committee Future Action Plan

- Late August 2025: Announce a medium-term management plan based on the 2030 Committee's activities
- Early November 2025: Release a final report alongside the first-half financial results

## 1 WG for strengthening the foundation

- Largely complete with this Interim Report
- Will conduct additional review if any issues are present

## 2 WG for growth strategy and business portfolio

- Late August 2025: Announce a medium-term management plan based on results of review by this WG

## 3 WG for capital allocation

- Late August 2025: Announce a medium-term management plan based on results of review by this WG

## 4 WG for governance

- Will go beyond putting governance system in place to review initiatives for enhancing effectiveness as well
- Will endeavor to bolster effectiveness of existing succession plan and is planning on releasing specific associated details in final report in November

## 5 WG for shareholder and investor relations

- Largely complete with this Interim Report
- Will conduct additional review if any issues are present

## 6 WG for capital policy

- Special committee currently reviewing various proposals by PE funds and business companies
- Currently working to prepare for release of medium-term management plan in August and final report in November

# Direction of Business Portfolio Examination

- We examine an ideal business portfolio that serves as an assumption upon the examination of its companywide strategy.
- In particular, regarding its Medical and Pharmaceuticals Business, the company separates this business into the manufacturing and marketing of pharmaceuticals and CDMO and reorganizes their positioning across the entire company from the standpoints of business performance up to that point, future growth strategies, affinity with other businesses, return on capital, and other aspects. After considering multiple options, we will determine the future course of action taking into account the time frame for implementation.

## Direction of business portfolio examination by 2030 Committee


### Examination of growth strategies

- Examine the environment, growth potential, room for the creation of new business, and other aspects of each business
- Input into quantitative business plans

### Re-examination of return on capital

- Re-examine B/S of each business, including future investments
- Calculate business ROICs reflecting actual performance, and develop medium- to long-term ROIC–WACC spread forecasts.


### Formulation of business portfolio policy



## Segregation of Roles Between 2030 Committee WG for Capital Policy and Special Committee

- The 2030 Committee is a meeting body on the business execution side. It only makes recommendations to the Board of Directors in the end. This makes it different from the special committee, which the Board of Directors makes inquiries to for recommendations.
- The 2030 Committee is a meeting body for the business execution side to ensure the objectivity and transparency of initiatives for solving management issues. In addition to the formulation of business plans that serve as the basis of various proposals, the review of ideal capital policy upon the execution of those business plans from the perspective of the executive side is also included in the scope of the 2030 Committee (the WG for capital policy).
- The Special Committee receives inquiries from the Board of Directors and conducts a comparative review of various proposals—including privatization—and the medium-term management plan examined and validated by the 2030 Committee. The results are then reported to the Board of Directors. Based on the Special Committee's recommendation, the Board makes a decision regarding the continuation of public listing or privatization.

### Our review system for decision-making on maintenance of listing and on privatization



# Future Review Schedule

- We will announce medium-term management plan at end of August 2025. Committee's final report scheduled to be subsequently made in November.

## Review schedule since receipt of acquisition proposal



While proceeding in parallel with the 2030 Committee, the overall process for examining capital policy will be established—including accepting additional proposals and facilitating due diligence for proposals from third parties—and carried out step by step following confirmation by the Special Committee.



None of the information herein constitutes any form of solicitation to purchase, sell, or otherwise trade in Taiyo Holdings' shares.

In addition, opinions, forward-looking statements, etc., herein are based on the judgment of the Company at the time of preparation. The Company makes no guarantees concerning the accuracy of such information, and these statements are subject to change without prior notice in the future.

The Company shall not assume any form of liability for any damages incurred based on the information in this document